DFFN
Income statement / Annual
Last year (2024), Diffusion Pharmaceuticals Inc.'s total revenue was $0.00,
and the percentage change from the previous year is not available.
In 2024, Diffusion Pharmaceuticals Inc.'s net income was -$16.29 M.
See Diffusion Pharmaceuticals Inc.,s key income statements, including revenue, expenses, profit, and income.
| Period |
FY-2024
|
FY-2022
|
FY-2021
|
FY-2020
|
FY-2019
|
FY-2018
|
FY-2017
|
FY-2016
|
FY-2015
|
FY-2014
|
| Period Ended |
12/31/2024 |
12/31/2022 |
12/31/2021 |
12/31/2020 |
12/31/2019 |
12/31/2018 |
12/31/2017 |
12/31/2016 |
12/31/2015 |
12/31/2014 |
| Operating Revenue |
$0.00 |
$0.00 |
$0.00 |
$0.00 |
$0.00 |
$0.00 |
$0.00 |
$0.00 |
$0.00 |
$0.00 |
| Cost of Revenue |
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
| Gross Profit |
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
| Gross Profit Ratio |
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
| Research and Development Expenses |
$18.80 M
|
$7.24 M
|
$8.50 M
|
$9.43 M
|
$6.62 M
|
$5.75 M
|
$5.09 M
|
$7.25 M
|
$3.85 M
|
$2.86 M
|
| General & Administrative Expenses |
$9.17 M
|
$8.74 M
|
$7.45 M
|
$6.44 M
|
$4.83 M
|
$6.17 M
|
$6.19 M
|
$11.09 M
|
$8.88 M
|
$4.76 M
|
| Selling & Marketing Expenses |
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
| Selling, General & Administrative Expenses |
$9.17 M
|
$8.74 M
|
$7.45 M
|
$6.44 M
|
$4.83 M
|
$6.17 M
|
$6.19 M
|
$11.09 M
|
$8.88 M
|
$4.76 M
|
| Other Expenses |
$0.00
|
$0.00
|
$93.42 K
|
$103.17 K
|
$97.92 K
|
$110.37 K
|
$0.00
|
$0.00
|
$6.36 K
|
-$2.28 M
|
| Operating Expenses |
$27.97 M
|
$15.97 M
|
$16.04 M
|
$15.98 M
|
$11.55 M
|
$12.03 M
|
$11.35 M
|
$18.37 M
|
$12.76 M
|
$7.94 M
|
| Cost And Expenses |
$0.00
|
$15.97 M
|
$16.04 M
|
$15.98 M
|
$11.55 M
|
$12.03 M
|
$11.35 M
|
$18.37 M
|
$12.76 M
|
$7.94 M
|
| Interest Income |
$1.94 M
|
$380.75 K
|
$137.49 K
|
$114.26 K
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
| Interest Expense |
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$151.65 K
|
$48.01 K
|
$29.69 K
|
$0.00
|
$273.50 K
|
| Depreciation & Amortization |
$0.00
|
-$209.00 K
|
$93.42 K
|
$103.17 K
|
$97.92 K
|
$110.37 K
|
$67.98 K
|
$25.34 K
|
$23.27 K
|
$566.26 K
|
| EBITDA |
-$18.23 M |
-$15.97 M |
-$7.31 M |
-$15.87 M |
$11.47 B |
$18.96 M |
-$14.15 M |
-$18.35 M |
-$1.66 M |
-$9.66 M |
| EBITDA Ratio |
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
| Operating Income Ratio |
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
| Total Other Income/Expenses Net |
$1.94 M
|
$380.75 K
|
$137.49 K
|
$114.26 K
|
$85.30 K
|
-$6.93 M
|
-$13.77 M
|
-$36.77 M
|
$6.36 K
|
-$2.56 M
|
| Income Before Tax |
-$16.29 M
|
-$15.59 M
|
-$24.54 M
|
-$15.86 M
|
-$11.47 M
|
-$18.81 M
|
-$2.42 M
|
-$18.40 M
|
-$23.82 M
|
-$17.17 M
|
| Income Before Tax Ratio |
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
| Income Tax Expense |
$0.00
|
-$381.00 K
|
-$444.00 K
|
-$1.68 M
|
$332.89 K
|
-$437.00 K
|
-$1.06 M
|
-$365.00 K
|
$0.00
|
-$2.82 M
|
| Net Income |
-$16.29 M
|
-$15.21 M
|
-$24.10 M
|
-$14.19 M
|
-$11.80 M
|
-$18.37 M
|
-$1.37 M
|
-$18.04 M
|
-$23.82 M
|
-$14.35 M
|
| Net Income Ratio |
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
| EPS |
-2.02 |
-7.46 |
-18.57 |
-19.76 |
-132 |
-283.28 |
-82.44 |
-1319.99 |
-6819.55 |
-7499.96 |
| EPS Diluted |
-2.02 |
-11.19 |
-18.57 |
-22.5 |
-132 |
-410.5 |
-80.45 |
-1319.99 |
-6819.55 |
-7499.96 |
| Weighted Average Shares Out |
$8.07 M
|
$2.04 M
|
$1.30 M
|
$717.76 K
|
$89.42 K
|
$64.85 K
|
$12.45 K
|
$13.64 K
|
$3.49 K
|
$1.91 K
|
| Weighted Average Shares Out Diluted |
$8.07 M
|
$1.36 M
|
$1.30 M
|
$717.76 K
|
$89.42 K
|
$64.85 K
|
$12.76 K
|
$13.64 K
|
$3.49 K
|
$1.91 K
|
| Link |
|
|
|
|
|
|
|
|
|
|
